Focal loss of long non-coding RNA-PRAL, as determinant of cell function and phenotype of hepatocellular carcinoma

Feo, Francesco; Simile, Maria M.; Pascale, Rosa M.

doi:10.21037/atm.2016.03.47

Cited by 14 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dysfunction in lncRNA may usually regulate biological systems by affecting epigenetic information and result in preference in cellular proliferation and even uncontrolled tumor development ( 26 ). The HCC is characterized by multiple abnormalities and always complicates traditional treatment and intervention ( 15 ). In previous reports, lncRNA DANCR can promote stemness features of HCC via regulating CTNNB1 ( 27 ).…”

Section: Discussionmentioning

confidence: 99%

“…The lncRNAs may participate in various biological processes including differentiation, angiogenesis, immune responses and apoptosis ( 9 , 10 ). Recent studies have suggested that the lncRNAs could act either as an oncogene or tumor suppressor with significant contributions to tumorigenesis of many cancers ( 11 – 15 ). For instances, lnc-DILC can inhibit liver cancer progression by modulating IL-6/STAT3 signaling ( 16 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The long non-coding RNA AK023948 enhances tumor progression in hepatocellular carcinoma

Zheng

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The long non-coding RNAs (lncRNAs) have been demonstrated to play pivotal roles in a broad range of processes including tumor biology. However, the exact contributions of lncRNAs to hepatocellular carcinoma (HCC) remain poorly defined. In current study, we have unraveled a novel function of AK023948 in HCC. We found that AK023948 was substantially upregulated in tumor tissues. Meanwhile, higher AK023948 expression correlated with poor survival. Upregulation of AK023948 expression can promote HepG2 and Hep3B proliferation and invasion in in vitro experiments. Furthermore, AK023948 also decreased tumor growth in vivo. The tumorigenic role of AK023948 was partially ascribed to PI3K/Akt/mTOR signaling and AK023948 knockdown decreased pathway activation and tumor growth. These data collectively suggest an oncogenic role for AK023948 and may provide potential insight into therapeutic intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The long non-coding RNA AK023948 enhances tumor progression in hepatocellular carcinoma

Zheng

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…The HEPG-2 is characterized as a progressive development of preneoplastic and neoplastic lesions. It can be classified as one of the most prevalent malignant diseases (Feo et al, 2016). Casp3 is one of the executioner caspase members and Bcl2 belongs to the apoptotic genes.…”

Section: The In Vitro Biological Activity Of Aqueous Purslane Extract Before and After Incorporating M-npsmentioning

confidence: 99%

“…Hydroxyproline is one of the most amino acids present in collagen following hydroxylation of proline moiety. It is produced in the ECM by activation of HSCs to preserve the integrity and function of the hepatocytes (Gabr et al, 2017). Its level in liver tissues comprises a superior limiting factor which could signify correct rates and progression of liver fibrogenesis (Wynn, 2008).…”

Section: The In Vivo Biological Activity Of Aqueous Purslane Extract Before and After Incorporating M-npsmentioning

confidence: 99%

Assessment of the Biological Activities of Egyptian Purslane (Portulaca oleracea) Extract after Incorporating Metal Nanoparticles, in Vitro and in Vivo Study

Aboulthana

Omar

Hasan

et al. 2022

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: Egyptian Purslane (Portulaca oleracea) is rich in omega-3 fatty acids and a wide range of vitamins and phyto-constituents that were absorbed slowly due to their high molecular weights. Therefore, this study was designed to accelerate the absorption of these phyto-constituents and hence increase their bioavailability by incorporating silver (Ag-NPs) and zinc oxide nanoparticles (ZnO-NPs) due to their impressive properties. Methods: The major phytoconstituents and different biological activities were quantified in aqueous extract before and after incorporating metal nanoparticles (M-NPs). The efficiency of ZnO-P. nano-extract was studied on cell cycle and apoptosis of human hepatocellular carcinoma (HEPG-2) cells. Then, both Ag-and ZnO-P. nano-extracts were studied against hepatic fibrosis induced by thioacetamide (TAA) in rats through undergoing different hematological and biochemical measurements in addition to the histopathological examination in hepatic tissues compared to the extract itself. Results: The ZnO-P. nano-extract showed significantly (P<0.05) higher antioxidant and scavenging activity due to the existence of higher total polyphenolic content. Also, it exhibited a significantly (P<0.05) higher inhibitory effect on acetyl cholinesterase (AChE) activity and higher cytotoxic activity against HEPG-2 cells. Therefore, ZnO-P. nano-extract was studied against the cell cycle and apoptosis of HEPG-2 cells compared to the extract itself. It was found that ZnO-P. nano-extract was safer than Ag-P. nano-extract. Both Ag-and ZnO-P. nano-extracts were studied against the hepatic fibrosis induced by thioacetamide (TAA) compared to the native extract. It was noticed that ZnO-P. nano-extract exhibited an ameliorative effect against hepatic fibrosis by decreasing levels of inflammatory and fibrotic markers significantly (P<0.05) more than Ag-P. nano-extract. Furthermore, it improved the antioxidant status of the hepatic tissue in addition to restoring the histopathological architecture of liver tissue. Conclusion: ZnO-P. nano-extract showed higher in vitro and in vivo biological activities than Ag-P. nano-extract and native P. extract itself.

show abstract

“…PRAL is a tumor suppressor lncRNA present on chromosome 17p13.1 usually in low levels in HCC patients and its overexpression inhibits tumor growth. This occurs due to the binding of PRAL to HSP90 which enhances its binding to p53, opposes MDM2 induced p53 degradation hence promoting HCC cell apoptosis[ 44 ]. Moreover, studying several deregulated genes in HCC revealed the downregulation of AF070632 associated with various cellular processes such as oxidation-reduction, cofactor binding in catabolic processes[ 45 ].…”

Section: Lncrna In Hccmentioning

confidence: 99%

Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis

Khodiry

Afify

Tayebi

2018

WJG

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common and aggressive cancers worldwide. HCC is the fifth common malignancy in the world and the second leading cause of cancer death in Asia. Long non-coding RNAs (lncRNAs) are RNAs with a length greater than 200 nucleotides that do not encode proteins. lncRNAs can regulate gene expression and protein synthesis in several ways by interacting with DNA, RNA and proteins in a sequence specific manner. They could regulate cellular and developmental processes through either gene inhibition or gene activation. Many studies have shown that dysregulation of lncRNAs is related to many human diseases such as cardiovascular diseases, genetic disorders, neurological diseases, immune mediated disorders and cancers. However, the study of lncRNAs is challenging as they are poorly conserved between species, their expression levels aren’t as high as that of mRNAs and have great interpatient variations. The study of lncRNAs expression in cancers have been a breakthrough as it unveils potential biomarkers and drug targets for cancer therapy and helps understand the mechanism of pathogenesis. This review discusses many long non-coding RNAs and their contribution in HCC, their role in development, metastasis, and prognosis of HCC and how to regulate and target these lncRNAs as a therapeutic tool in HCC treatment in the future.

show abstract

Focal loss of long non-coding RNA-PRAL, as determinant of cell function and phenotype of hepatocellular carcinoma

Cited by 14 publications

References 20 publications

The long non-coding RNA AK023948 enhances tumor progression in hepatocellular carcinoma

The long non-coding RNA AK023948 enhances tumor progression in hepatocellular carcinoma

Assessment of the Biological Activities of Egyptian Purslane (Portulaca oleracea) Extract after Incorporating Metal Nanoparticles, in Vitro and in Vivo Study

Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis

Contact Info

Product

Resources

About